All News

New research showed that the BNT162b2 XBB vaccine was capable of reducing hospitalizations and emergency department and urgent care visits due to COVID-19 in children aged 5 to 17 years.

Read about the diverse array of research presented at this year's meeting, including novel technological advancements and insights into disease progression in multiple sclerosis (MS).

Real-world study compares the efficacy and safety of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), finding that axi-cel provides superior progression-free survival but with higher toxicity.

This recent study sheds light on a remaining gap in spinal muscular atrophy (SMA) research and care considerations: the impact of spinal motor neuron (SMN) copy number.

A Yale School of Medicine team has created lists of criteria to help clinicians determine when next-generation sequencing (NGS) is appropriate for a patient with a myeloid neoplasm (MN), and when it is not.

Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, with key research presented on immune thrombocytopenia, hemophilia, and multiple myeloma.

Alice W. Lee, PhD, MPH, of California State University, Fullerton, discusses her study on ovarian cancer survival disparities among disaggregated Asian American subgroups, emphasizing the need for a subgroup-specific approach in cancer research.

Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction in disease progression or death compared with standard-of-care endocrine therapy.

Patients with dry eye associated with contact lenses had significant improvement in visual acuity and their Ocular Surface Disease Index (OSDI) score after a month of using hydrogen peroxide.

Komal Jhaveri, MD, FACP, breast oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center, presents findings from the EMBER-3 trial evaluating imlunestrant for patients with advanced breast cancer.

Yi Lin, MD, PhD, hematologist and oncologist, Mayo Clinic, discusses the efficacy of ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor T-cell therapy vs standard treatments for patients with multiple myeloma.

Conventional parameters for risk stratification prognosis for patients with low-risk myelodysplastic neoplasms, especially bone marrow blast percentage, drop their clinical significance once molecular lesions are included in prognostic scores.

Novel strategies in the VISIBLE trial set a new standard for recruiting and retaining diverse participants with skin of color in dermatology clinical trials.

Strategies to help patients with chronic conditions stay healthy and avoid complications this winter.

Two posters presented at the 2024 American Society of Hematology meeting bolster evidence supporting the long-term clinical benefits of ruxolitinib for polycythemia vera and chronic graft-vs-host disease.

Older adults on Medicare Advantage had improved adherence and odds of a test return when a stool test was mailed to them for screening of colorectal cancer (CRC).

The study is the first to evaluate a fixed-duration regimen of venetoclax, the first-generation BCL2 inhibitor, with a second-generation Bruton tyrosine kinase inhibitor, acalabrutinib, in chronic lymphocytic leukemia (CLL).

Researchers found patients reporting greater disease burden and lower health-related quality of life (HRQoL) are more likely to switch to biologic therapies, regardless of clinician-rated disease severity.

New insights underscore the value of considering sleep variability when addressing inequities in pediatric sleep health.

Research presented at the 66th American Society of Hematology Annual Meeting revealed that a genetic variant enriched in Andean populations, associated with reduced inflammation and improved response to ropeginterferon-α, could guide more precise treatments for polycythemia vera (PV) and essential thrombocythemia.

The inMIND trial was the first to examine dual targeting of CD19 and CD20 in follicular lymphoma.

Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health, discussed the decision-making process for selecting between fixed-duration options and continuous Bruton tyrosine kinase inhibitor (BTKi) therapy for patients with chronic lymphocytic leukemia (CLL).

Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL), though questions remain about which patients would benefit most from the regimen.

Oussama Wazni, MD, Cleveland Clinic, discusses insights from the OPTION trial and their potential implication on guidelines for post-ablation management in atrial fibrillation.

These data from the Environmental Protection Agency were presented at the Society for Risk Analysis annual meeting.

Implementing an individualized starting dose (ISD) of niraparib (Zejula; GSK) reduced severe hematologic adverse event (AE) management costs by 48% compared with a fixed starting dose (FSD) in US patients with ovarian cancer.

Higher dietary magnesium intake is associated with a reduced risk of frailty in patients with chronic obstructive pulmonary disease (COPD), emphasizing its potential role in improving clinical outcomes.

This pair of posters presented at the 66th American Society of Hematology Annual Meeting & Exposition provides updates on epcoritamab, currently being investigated in the Epcore NHL-1 trial.

The phase 3 AQUILA study showed a 63.1% progression-free rate at 5 years with daratumumab versus 40.8% with active monitoring.